... Jan 21
Nevro Corp, today announced that the company has submitted a pre-market approval supplement to the U.S. Food and Drug Administration (FDA) for HF10® ... Dec 29
Teplizumab, Provention Bio’s lead drug candidate, is an anti-CD3 monoclonal antibody (mAb) being developed for the delay or prevention of type 1 diabetes ... Aug 29
Saiba AG and AGC Biologics come together for developing Coronavirus vaccine... Jun 17
-Advertisements-